CMS certification 363300
Cincinnati Children's Hospital Medical Center
3333 Burnet Avenue, Cincinnati, OH 45229
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
3,053 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 377 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Nurse Practitioner | 507 |
| Pediatrics | 407 |
| Case Manager/Care Coordinator | 104 |
| Pediatric Anesthesiology | 98 |
| Pediatric Hematology-Oncology | 88 |
| Social Worker | 86 |
| Clinical | 81 |
| Clinical Child & Adolescent | 79 |
| Psychologist | 77 |
| Neonatal-Perinatal Medicine | 71 |
| Pediatric Cardiology | 66 |
| Physician Assistant | 66 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $15.7M
- 2020 $20.6M
- 2021 $19.3M
- 2022 $18.2M
- 2023 $13.3M
- 2024 $10.8M
- 2025 $14.5M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Speaking, teaching and other services | $1.4M | 62 |
| Grants | $748,074 | 26 |
| Royalties and licensing fees | $415,932 | 13 |
| Charitable contributions | $270,250 | 3 |
| Space rental and facility fees | $102,874 | 22 |
| Debt forgiveness | $34,612 | 13 |
| Consulting fees | $29,100 | 4 |
| Education | $27,317 | 3 |
| Faculty and speaker fees for medical education | $5,000 | 1 |
| Medical devices and supplies on long-term loan | $396 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1M | 9 |
| Pfizer INC. | $1M | 49 |
| Exeltis, USA Inc. | $963,651 | 13 |
| Sobi, INC | $834,065 | 13 |
| Genzyme Corporation | $770,336 | 27 |
| Regeneron Pharmaceuticals, Inc. | $633,303 | 37 |
| Eli Lilly and Company | $594,615 | 19 |
| Merck Sharp & Dohme LLC | $527,145 | 11 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) E.R. Squibb & Sons, L.L.C. | $851,073 |
| An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosid… GENZYME CORPORATION · NCT04910776 | $476,341 |
| A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECT… Regeneron Pharmaceuticals, Inc. · NCT05788536 | $411,908 |
| A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD Amicus Therapeutics, Inc. | $390,146 |
| Modeling Immune-mediated Steatohepatitis using Human Organoids Daiichi Sankyo Inc. | $320,000 |
| A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esoph… AstraZeneca Pharmaceuticals LP | $317,364 |
| A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (AZALEA) Janssen Research & Development, LLC | $293,018 |
| AN OPEN-LABEL TRIAL TO ADDRESS THE SAFETY OF THE SMARTFLOW MR-COMPATIBLE VENTRICULAR CANNULA FOR ADMINISTERING ELADOCAGENE EXUPARVOVEC TO PEDIATRIC S… PTC Therapeutics, Inc. · NCT04903288 | $256,659 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Cincinnati Children's Hospital Medical Center
Does Cincinnati Children's Hospital Medical Center have an emergency room?
Yes. CMS lists emergency services at Cincinnati Children's Hospital Medical Center.
Does Cincinnati Children's Hospital Medical Center receive money from drug and device companies?
Drug and device makers reported $14.5M in payments to Cincinnati Children's Hospital Medical Center for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.